About Bioceltix
Bioceltix was founded in 2016 by a team of scientists driven by curiosity and a deep love for animals; combined with an understanding of business realities. That’s why we are at the forefront of a revolution in the development of veterinary biologics based on mesenchymal stem cells (MSCs).
At our core we ask, if pet owners treat their animal companions as part of the family, why should they be offered less advanced treatment options when they are in need?
Our mission
Veterinary medicine is sounding the alarm. The chronic use of anti-inflammatory drugs in companion animals leads to a long list of adverse side effects. The data speaks for itself: more than 20% of dogs suffer from degenerative joint disease, and 15% are affected by atopic dermatitis. Among horses, nearly 30% experience joint inflammation, manifesting as impaired mobility and lameness. These show how human health conditions are reflected in our animal counterparts.
Meanwhile, clinical studies confirm that biologics and cell therapies offer a safe and effective alternative to symptomatic pharmaceutical treatment – which has long relied on conventional chemical painkillers and nonsteroidal or steroidal anti-inflammatory drugs.
At Bioceltix, we are developing innovative therapies designed to improve both the quality and comfort of life for four-legged patients. In response to the rising incidence of inflammatory and autoimmune conditions, we are addressing the most urgent therapeutic needs in veterinary care.
Our answer to the challenges of veterinary medicine?
In developing biological therapies, we leverage the analgesic and anti-inflammatory properties of stem cells. The therapeutic effect is driven by biologically active substances that naturally occur in the patient’s body. Our medicinal products, through strong immunomodulatory activity, suppress inflammation and consequently enable the regeneration of tissue damaged by disease.
Biological drugs provide long-lasting effects and are associated with a limited number of side effects, in contrast to most traditional chemical pharmaceuticals.
Caring for them, as they care for us.
Our portfolio
BCX-CM-J
BCX-CM-AD
BCX-EM
BCX-CM-Sec
Our Approach
Safety
We foster animal health at every stage of research. Our products undergo rigorous Target Animal Safety (TAS) studies.
Efficacy
We operate in line with the highest standards and pharmaceutical industry regulations. Efficacy is validated in multicenter clinical trials.
Quality
We implement an advanced quality control system that ensures comprehensive stability of the product – the core of allogeneic therapy.